Bromide

Bromide

SCHEMBL9281172

Br.Br.NCCN1CCCC1

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SIGMAR1 known ✓ Q99720 1/20 0.39
ALOX15 P16050 1/20 0.71
HRH3 Q9Y5N1 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.42
CARM1 Q86X55 1/20 0.42
PRMT6 Q96LA8 1/20 0.42
PRMT8 Q9NR22 1/20 0.42
LMNA P02545 1/20 0.41
ACE2 Q9BYF1 1/20 0.40
MAPT P10636 3/20 0.39
ALDH1A1 P00352 2/20 0.39
POLB P06746 1/20 0.39
KEAP1 Q14145 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL6373609 1.00
SCHEMBL82264 0.97
SCHEMBL7672268 0.97
SCHEMBL476405 0.94 ALOX15 (0.71) ALOX15HRH3L3MBTL1CARM1PRMT6
Hydrochloric Acid SCHEMBL7021996 0.94 ALOX15 (0.71) ALOX15HRH3L3MBTL1CARM1PRMT6
SCHEMBL5143305 0.94 ALOX15 (0.71) ALOX15HRH3L3MBTL1CARM1PRMT6
Hydrochloric Acid SCHEMBL9031336 0.94 ALOX15 (0.71) ALOX15HRH3L3MBTL1CARM1PRMT6
SCHEMBL5663473 0.94 ALOX15 (0.71) ALOX15HRH3L3MBTL1CARM1PRMT6
SCHEMBL6180747 0.94
Hydrochloric Acid SCHEMBL73680 0.94

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9844516-B2 Sigma ligands for use in the prevention and/or treatment of post-operative pain Laboratorios De Dr. Esteve (ES) 2017-12-19 US disclosed
US-9789115-B2 Use of sigma ligands in opioid-induced hyperalgesia LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2017-10-17 US disclosed
US-9782483-B2 Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy LABORATORIES DEL DR. ESTEVE, S.A. (ES) 2017-10-10 US disclosed
US-20130324535-A1 USE OF SIGMA LIGANDS IN BONE CANCER PAIN LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2013-12-05 US disclosed
EP-2646025-A1 USE OF SIGMA LIGANDS IN BONE CANCER PAIN Laboratorios Del. Dr. Esteve, S.A. (ES) 2013-10-09 EP disclosed
US-20130158033-A1 USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2013-06-20 US disclosed
EP-2600863-A2 USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA Laboratorios Del. Dr. Esteve, S.A. (ES) 2013-06-12 EP disclosed
US-20130109692-A1 SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2013-05-02 US disclosed
EP-2571501-A1 SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY Laboratorios Del. Dr. Esteve, S.A. (ES) 2013-03-27 EP disclosed
EP-2531191-A1 SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POSTOPERATIVE PAIN Laboratorios Del. Dr. Esteve, S.A. (ES) 2012-12-12 EP disclosed
US-20120302568-A1 SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POST-OPERATIVE PAIN LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-11-29 US disclosed
WO-2012072782-A1 USE OF SIGMA LIGANDS IN BONE CANCER PAIN LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-06-07 WO disclosed
WO-2012016980-A2 USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302568-A1 SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POST-OPERATIVE PAIN OPRL1, OPRK1, SIGMAR1 SIGMAR1 3/4885ALOX15 402/4885HRH3 59/4885
US-20130158033-A1 USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA OPRL1, OPRK1, OPRM1 SIGMAR1 5/4885ALOX15 737/4885HRH3 35/4885
US-20130109692-A1 SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY SIGMAR1, SFN, TMEM97 SIGMAR1 1/4885ALOX15 2981/4885HRH3 49/4885
US-20130324535-A1 USE OF SIGMA LIGANDS IN BONE CANCER PAIN SIGMAR1, OPRL1, OPRK1 SIGMAR1 1/4885ALOX15 1980/4885HRH3 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.